Time | |
10.30-11.00 AM | Opening: Industry Trends Impacting Pharmaceutical Packaging The pharmaceutical packaging market has constantly been growing and changing in the past few years. The increasing need for sustainability in pharma packaging, more sophisticated and trackable packaging to advance safety and the rising demand for autoinjectors are drivers of innovation and differentiation. We invite you to listen to L.E.K. consulting’s view on recent and likely future pharmaceutical packaging developments and trends. Karin von Kienlin, Partner, L.E.K. Consulting LLC
|
| SUSTAINABLE MATERIALS |
11.10-11.40 AM | Sustainable Primary Pharma Packaging and Benefits of PP For the past 20 years in healthcare, Polypropylene (PP) has been the most utilized plastic across a range of applications, from high-risk applications such as IV parenteral packaging to medical devices and diagnostics. PP offers alternatives to glass, metal and other plastics, such as PS or PVC. The pressure to find more environmentally friendly packaging solutions has increased significantly. SÜDPACK Medica’s Ecoterm™ Pharma PP pushes thermoforming of PP systems to a new level in terms of barrier level and shrinkage control. The change from PVC now becomes much easier. Halogen-free alternatives are a key consideration for making these sustainable decisions. Our expert speaker will talk about the ideal blister packaging and the reason why PP is the recommended material for oral solid dose packaging. You will hear more about PP as a polymer, advantages, focus areas, and recent LCA studies including the topic of sustainability. Will you join us? - Michael Hermann, Head of R&D, Südpack Medica
- Pieter van Gool, Business Development Manager, Südpack Medica
- Jürgen Bodenmüller, Director of Business Development, Südpack Medica
|
11.50-12.20 PM | Delivering the Difference: Know-how and Cutting-Edge Technology The presentation will focus on pressing over the pain points of Pharma Manufacturing, where we present the ECOSYSTEM of Körber Pharma as a great solution. I plan to address the burning questions - What is an Ecosystem and why is it so important in Pharma Manufacturing? The specific details on exploring Körber as a brand and its expertise in Pharma machinery (Packaging for parenteral, vaccines, blister, capsules, etc, handling/buffer/conveyer machines and Visual Inspection machines (automatic, semi-automatic visual inspection and manual machines)), Software (MES and other software innovations), Materials for pharma packaging (our green footprint apart from other advantages, e.g. test battery) as well as Consulting in Pharma Manufacturing, including topics such Pharma 4.0, validation (CSV, CQV and process validation), vertical and horizontal integration and best practices, will be included. The presentation would be rather in an interactive format and would aim to show the audience the relevance of our motivation tag line – Delivering the Difference in Pharma Manufacturing. Dr. Sukhada Chaturvedi, International Account Manager, Körber Pharma |
| DIGITAL & CONNECTIVITY |
1:00-1:30 PM | Patient journey as the foundation for holistic connected device development Mark Tunkel, Global Category Director Services, Nemera |
1:40-2:10 PM | NFC & RFID Technologies: Adding Value to Drugs and Medical Devices with Connectivity Connecting medication and medical devices to the internet can enhance product protection, improve patient safety and outcomes, and optimize processes along complex supply chains. NFC-RFID technologies are increasingly used to provide connectivity benefits more securely and efficiently, ensuring that pharma products are safer and more effective to use. Applications include reliable counterfeit and integrity protection, automated supply chain and inventory management, simplified drug delivery and self-medication, and more. As a prominent technology leader NXP strives to build a smarter world on secure connections, with designs that connect, sense, think and act intelligently, all to enhance people’s lives. Visit our workshop and find out how our multifunctional NFC-RFID solutions bring added safety, security and connectivity benefits to manufacturers, healthcare providers, and patients alike. Sylvia Kaiser-Kershaw, Senior Global Marketing Manager, NXP Semiconductors Frederic Vicentini, Senior Manager Business Development RFID/NFC/IOT EMEA, NXP Semiconductors |
2:20-2:50 PM | Enabling Digital Health Solutions with the Connected BD UltraSafe Plus™ Passive Needle Guard Sub-optimal adherence and persistence to treatment continue to be significant challenges for both on-market drugs and investigational products in clinical development. This is especially true for self-administered medications for chronic disease patients, hence driving the need for improved treatment intake monitoring technologies. To answer this need, BD and Biocorp have joined forces to develop a connected version of the BD UltraSafe Plus™ Passive Needle Guard that facilitates the traceability of injections. During this workshop, the speakers will welcome you for an interactive presentation featuring the following topics:
- Unmet needs in clinical & real-life settings: the challenge of treatment adherence •
- The solution: overview of the connected BD UltraSafe Plus™ Passive Needle Guard, technical details and value proposition for different stakeholders
- Interactive demo session
- Use cases: how the connected BD UltraSafe Plus™ Passive Needle Guard can fit into clinical and real-life practices
Hervé Monchoix, Strategic Innovation Leader, BD Medical - Pharmaceutical Systems Antoine Millot, Business Developmer, Biocorp Arnaud Guillet, VP Business Development, Biocorp |
| AUTOINJECTORS |
3:00-3:30 PM | Case Study of a Biosimilar Drug Launched Globally Using Integrated CDMO Solution Biologics is expected to see double-digit growth. Moving biologics drug administration from hospital to home environment is one of the key trends to shape the future of the global biologics industry. One of the most proven strategies adopted by many biopharmaceutical companies is the combination of PFS with autoinjectors or safety devices, nevertheless, there are several requirements to be met in case of combining primary packaging and drug delivery device. Having the right partner for development and manufacturing will be the key for Biopharmaceutical companies to reduce time to market and project risk. Terumo’s unique capabilities are integrated into CDMO solutions and offer end-to-end services starting from primary container and drug-device combination product development, fill & finish, device assembly, regulatory support, and commercial launch. We would like to highlight this with a case study of a biosimilar drug used in combination with Autoinjector which has been launched globally. Anil Busimi, Vice President, Strategy & Marketing, Terumo Pharmaceutical Solutions (TPS) |
3:40-4:10 PM | Collaborating to Simplify Device Development and Optimize Glass Solutions for Auto-Injectors Advances in auto-injector design now provide the option to use both 1ml and 2.25mL syringes plus employ technology to adapt to varying fill volumes and viscosities all whilst maintaining the same device form. This provides a solution for the formulation changes that take place during drug development, clinical trials, and life cycle management. When looking at the performance of any parenteral injection device, the drug containment systems play a crucial role. Auto-injector performance and functionality are strictly linked to key dimensional tolerances of glass syringes. We will illustrate the importance of syringe design to ensure these requirements and how monitoring dimensional parameters at an early stage of the development is key to ensure the intended use and ultimately work to preserve patients’ safety. Benefits of tight collaboration between device designer and manufacturer will also be discussed. - Adam Stops, Head of Product Management Drug Delivery Systems, Stevanato Group
- Richard Harrison, Product Development Manager, Owen Mumford Pharmaceutical Services
|
4.20-4.50 PM | A new polycarbonate for drug delivery devices to lower carbon footprint and reduce plastic waste To meet the increasing demand for materials with lower carbon footprint and contribute to decreasing plastic waste in the Healthcare industry, Covestro is introducing Makrolon® 3638 polycarbonate that offers a unique combination of properties for drug delivery devices and pharmaceutical storage applications. Specifically, Makrolon® 3638 polycarbonate offers best-in-class resistance to hand lotions and outstanding low-temperature impact strength that can allow for autoinjectors or pharmaceutical containers to meet stringent durability requirements. Furthermore, like many materials already offered by Covestro, Makrolon® 3638 can be available in a version with significantly lower carbon footprint. This presentation will discuss the new materials’ properties and illustrate how it can play a role to reduce plastic waste with an all-polycarbonate materials based concept device that demonstrates how simplified material recovery and excellent recycling stability play a key role in facilitating open and closed loops. Bernd Garska, Technical Marketing Manager - Healthcare EMEA, Covestro |